Invesco
MRTX

Invesco’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Invesco’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-65,657
Closed -$3.86M – 3987
2023
Q4 		$3.86M Buy
65,657
+5,589
+9% +$314K ﹤0.01% 2362
2023
Q3 		$2.62M Sell
60,068
-24,004
-29% -$857K ﹤0.01% 2499
2023
Q2 		$3.04M Sell
84,072
-71,287
-46% -$2.94M ﹤0.01% 2483
2023
Q1 		$5.78M Sell
155,359
-278,217
-64% -$12.5M ﹤0.01% 2150
2022
Q4 		$19.6M Sell
433,576
-147,332
-25% -$9.53M 0.01% 1386
2022
Q3 		$40.6M Buy
580,908
+138,196
+31% +$10.2M 0.01% 979
2022
Q2 		$29.7M Buy
442,712
+15,723
+4% +$1,000K 0.01% 1148
2022
Q1 		$35.1M Buy
426,989
+29,576
+7% +$3.02M 0.01% 1177
2021
Q4 		$58.3M Sell
397,413
-291,501
-42% -$45.3M 0.01% 985
2021
Q3 		$122M Buy
688,914
+350,818
+104% +$56.4M 0.03% 732
2021
Q2 		$54.6M Buy
338,096
+8,916
+3% +$1.43M 0.01% 1046
2021
Q1 		$56.4M Sell
329,180
-173,436
-35% -$34.3M 0.02% 1008
2020
Q4 		$110M Sell
502,616
-10,604
-2% -$2.29M 0.03% 689
2020
Q3 		$85.2M Buy
513,220
+485,943
+1,782% +$66.5M 0.03% 700
2020
Q2 		$3.11M Sell
27,277
-3,259
-11% -$316K ﹤0.01% 2249
2020
Q1 		$2.35M Sell
30,536
-433,134
-93% -$38.8M ﹤0.01% 2308
2019
Q4 		$59.7M Sell
463,670
-357,386
-44% -$34.5M 0.02% 926
2019
Q3 		$64M Sell
821,056
-181,739
-18% -$17.1M 0.02% 873
2019
Q2 		$103M Buy
1,002,795
+769,429
+330% +$59.9M 0.03% 665
2019
Q1 		$17.1M Buy
233,366
+106,130
+83% +$7.22M 0.01% 1318
2018
Q4 		$5.4M Sell
127,236
-226,295
-64% -$9.02M ﹤0.01% 1898
2018
Q3 		$16.7M Buy
353,531
+99,590
+39% +$5.54M 0.01% 1396
2018
Q2 		$12.5M Buy
+253,941
New +$9.59M ﹤0.01% 1529
2015
Q3 		– Sell
-175
Closed -$6K – 4039
2015
Q2 		$6K Buy
+175
New +$5.16K ﹤0.01% 4142

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Invesco's MRTX Position: Q1 2024 in Review

Invesco sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 65,657 shares — an estimated $3.86M sold.

Invesco first reported a position in MRTX in Q2 2015 and held it in 24 quarters. The position peaked at $122M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Invesco reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Invesco sold 65,657 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.86M.
  • Invesco first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 24 quarters.
  • Invesco's Mirati Therapeutics, Inc. Common Stock position peaked at $122M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Invesco's 13F filing for Q1 2024, filed 14 May 2024.